Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 512,893
  • Shares Outstanding, K 85,340
  • Annual Sales, $ 420 K
  • Annual Income, $ -70,790 K
  • 36-Month Beta 2.23
  • Price/Sales 1,235.44
  • Price/Cash Flow N/A
  • Price/Book 4.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.20
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.19 +13.87%
on 11/21/18
6.51 -9.22%
on 12/03/18
+0.42 (+7.65%)
since 11/16/18
3-Month
5.06 +16.80%
on 10/24/18
6.68 -11.53%
on 09/28/18
+0.41 (+7.45%)
since 09/17/18
52-Week
4.41 +34.01%
on 12/19/17
6.69 -11.66%
on 05/16/18
+1.27 (+27.37%)
since 12/15/17

Most Recent Stories

More News
Aurinia Establishes at-the-Market Facility

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") today announced that it has entered into an Open Market Sale Agreement (the "Sale Agreement") with Jefferies...

AUPH : 5.86 (-2.50%)
Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abeona Therapeutics Inc. (NASDAQ:ABEO),...

IMMY : 5.63 (-3.43%)
CYTK : 7.47 (-2.99%)
AUPH : 5.86 (-2.50%)
LNT : 44.57 (-1.65%)
GLDD : 7.20 (-1.50%)
ABEO : 7.40 (+0.41%)
Aurinia to Participate in November Investor Conferences

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.

AUP.TO : 7.90 (-2.59%)
AUPH : 5.86 (-2.50%)
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -23.53% and 476.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

AUPH : 5.86 (-2.50%)
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development

--Phase II data for the treatment of dry eye expected in January 2019

AUPH : 5.86 (-2.50%)
Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH) (TSX:AUP) today announced that it will release its third quarter 2018 financial results on Thursday, November 8, 2018, after the market closes....

AUP.TO : 7.90 (-2.59%)
AUPH : 5.86 (-2.50%)
New Research: Key Drivers of Growth for Haverty Furniture Companies, BLACKLINE INC, MagnaChip Semiconductor, Kinross Gold, Aurinia Pharmaceuticals, and NEXEO SOLUTIONS -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Haverty Furniture Companies,...

NXEO : 8.60 (-1.94%)
AUPH : 5.86 (-2.50%)
KGC : 2.98 (+3.47%)
HVT : 19.40 (+0.83%)
BL : 38.65 (-2.18%)
MX : 6.77 (-0.15%)
Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher

Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

AUPH : 5.86 (-2.50%)
PCRX : 44.05 (-2.67%)
Aurinia to Participate in Upcoming Investor Conferences

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences.

AUP.TO : 7.90 (-2.59%)
AUPH : 5.86 (-2.50%)
Aurinia Reports First Quarter Financial Results and Operational Highlights

--Trials in FSGS and Dry Eye expected to begin in June 2018

AUP.TO : 7.90 (-2.59%)
AUPH : 5.86 (-2.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade AUPH with:

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

2nd Resistance Point 6.26
1st Resistance Point 6.14
Last Price 5.86
1st Support Level 5.92
2nd Support Level 5.82

See More

52-Week High 6.69
Last Price 5.86
Fibonacci 61.8% 5.82
Fibonacci 50% 5.55
Fibonacci 38.2% 5.28
52-Week Low 4.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar